Th - Therapeutic options for melanoma 1

Question 1

Which patient feels better: WHO 0 or WHO 4?

Answer 1

WHO 0

Question 2

(Low/high) LDH is a negative prognostic factor for efficacy of ipilimumab in metastatic melanoma. LDH has to be (</>)2 than normal.

Answer 2

High, < (less)

Question 3

The (less/more) mutations, the better ipilimumab works.

Answer 3

More

Question 4

What should patients with high bilirubin, ASAT and ALAT be treated with in addition to ipilimumab?

Answer 4

Prednisone.

Question 5

What happens if we give ipilimumab? (molecularly, explain complicated)

Answer 5

Anti-PD1 or anti-PDL1 block the PDL1-PD1 interaction in the tumor resulting in an enhanced T cell anti-tumor activity

Question 6

To which patients is BRAF-targeting therapy given to?

Answer 6

Patients with Braf600E/K mutation

Question 7

What is the biologic rationale for combined use of ipilimumab and nivolumab?

Answer 7

Ipilimumab blocks PD-1 in the lymph node, nivolumab blocks CTLA-4 in the tumor.